BRAF and melanoma: One randomised trial suggests the addition of trametinib to paclitaxel improves ORR (42% vs 13%, P = 0.01) and PFS (5.2 vs 3.4 months, P = 0.04) but not OS (9.4 vs 10.8 months, P = 0.18) compared to paclitaxel monotherapy in BRAF wild-type melanoma, although this was not compared against trametinib alone [98].